NEU Stock Overview
Engages in the distribution of pharmaceuticals to pharmacies, hospitals, and other outpatient medical care facilities in Poland.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for NEU from our risk checks.
NEUCA S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł912.00 |
| 52 Week High | zł969.00 |
| 52 Week Low | zł630.00 |
| Beta | 0.39 |
| 1 Month Change | -0.76% |
| 3 Month Change | 3.17% |
| 1 Year Change | 21.76% |
| 3 Year Change | 12.73% |
| 5 Year Change | 225.71% |
| Change since IPO | 2,011.11% |
Recent News & Updates
Recent updates
NEUCA (WSE:NEU) Seems To Use Debt Quite Sensibly
Mar 08
Returns On Capital At NEUCA (WSE:NEU) Have Stalled
Dec 29Here's Why NEUCA (WSE:NEU) Can Manage Its Debt Responsibly
Dec 05NEUCA (WSE:NEU) Hasn't Managed To Accelerate Its Returns
Apr 16An Intrinsic Calculation For NEUCA S.A. (WSE:NEU) Suggests It's 32% Undervalued
Jan 17Capital Investment Trends At NEUCA (WSE:NEU) Look Strong
Oct 25Here's Why We Think NEUCA (WSE:NEU) Is Well Worth Watching
Aug 04Is There An Opportunity With NEUCA S.A.'s (WSE:NEU) 34% Undervaluation?
Jul 01Returns On Capital At NEUCA (WSE:NEU) Have Stalled
Jun 18NEUCA (WSE:NEU) Is Increasing Its Dividend To zł11.50
Apr 21NEUCA (WSE:NEU) Is Increasing Its Dividend To zł11.50
Apr 07NEUCA (WSE:NEU) Knows How To Allocate Capital
Mar 15Does NEUCA (WSE:NEU) Have A Healthy Balance Sheet?
Jan 03Is NEUCA (WSE:NEU) Using Too Much Debt?
Jun 14With EPS Growth And More, NEUCA (WSE:NEU) Is Interesting
May 19Investors Shouldn't Overlook NEUCA's (WSE:NEU) Impressive Returns On Capital
Mar 30A Look At The Fair Value Of NEUCA S.A. (WSE:NEU)
Mar 15Did You Participate In Any Of NEUCA's (WSE:NEU) Fantastic 211% Return ?
Mar 02Is Now The Time To Put NEUCA (WSE:NEU) On Your Watchlist?
Feb 18Is NEUCA S.A.'s(WSE:NEU) Recent Stock Performance Tethered To Its Strong Fundamentals?
Feb 06Should You Rely On NEUCA's (WSE:NEU) Earnings Growth?
Jan 26
The Case For NEUCA S.A. (WSE:NEU): Could It Be A Nice Addition To Your Dividend Portfolio?
Jan 15Is NEUCA (WSE:NEU) Using Too Much Debt?
Jan 04The Trend Of High Returns At NEUCA (WSE:NEU) Has Us Very Interested
Dec 23Is NEUCA S.A. (WSE:NEU) Trading At A 24% Discount?
Dec 13Could The NEUCA S.A. (WSE:NEU) Ownership Structure Tell Us Something Useful?
Dec 03Announcing: NEUCA (WSE:NEU) Stock Increased An Energizing 122% In The Last Three Years
Nov 23Shareholder Returns
| NEU | PL Healthcare | PL Market | |
|---|---|---|---|
| 7D | -5.9% | -4.3% | -1.7% |
| 1Y | 21.8% | 29.2% | 21.5% |
Return vs Industry: NEU underperformed the Polish Healthcare industry which returned 29.2% over the past year.
Return vs Market: NEU matched the Polish Market which returned 21.5% over the past year.
Price Volatility
| NEU volatility | |
|---|---|
| NEU Average Weekly Movement | 2.5% |
| Healthcare Industry Average Movement | 4.9% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in PL Market | 9.2% |
| 10% least volatile stocks in PL Market | 3.4% |
Stable Share Price: NEU has not had significant price volatility in the past 3 months.
Volatility Over Time: NEU's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 4,633 | Piotr Sucharski | www.neuca.pl |
NEUCA S.A. engages in the distribution of pharmaceuticals to pharmacies, hospitals, and other outpatient medical care facilities in Poland. It operates through Pharmaceutical Wholesale, Manufacture of Pharmaceuticals, Outpatient Medical Care Clinics, Clinical Trials, and Insurance Activities segments. The company also provides advertising and marketing services; pharmaceutical products under its own brand; clinical trial, agency, financial, road cargo transport, medical practice, software, hospital, property management, scientific research and development, and IT services; clinical and experimental development services in biotechnology; therapeutic research services for new drug and medical product developments; and health, property, and other personal insurance products.
NEUCA S.A. Fundamentals Summary
| NEU fundamental statistics | |
|---|---|
| Market cap | zł4.07b |
| Earnings (TTM) | zł154.95m |
| Revenue (TTM) | zł11.97b |
26.3x
P/E Ratio0.3x
P/S RatioIs NEU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NEU income statement (TTM) | |
|---|---|
| Revenue | zł11.97b |
| Cost of Revenue | zł10.63b |
| Gross Profit | zł1.34b |
| Other Expenses | zł1.18b |
| Earnings | zł154.95m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 29, 2024
| Earnings per share (EPS) | 34.68 |
| Gross Margin | 11.18% |
| Net Profit Margin | 1.29% |
| Debt/Equity Ratio | 39.7% |
How did NEU perform over the long term?
See historical performance and comparisonDividends
1.6%
Current Dividend Yield41%
Payout RatioDoes NEU pay a reliable dividends?
See NEU dividend history and benchmarks| NEUCA dividend dates | |
|---|---|
| Ex Dividend Date | Jun 12 2024 |
| Dividend Pay Date | Jun 25 2024 |
| Days until Ex dividend | 9 days |
| Days until Dividend pay date | 22 days |
Does NEU pay a reliable dividends?
See NEU dividend history and benchmarks